ConductScience.org, home

Paper32039434

Structural insights into the promutagenic bypass of the major cisplatin-induced DNA lesion.

Ouzon-Shubeita H and 2 others. Biochem J, 2020. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Structural insights into the promutagenic bypass of the major cisplatin-induced DNA lesion. Papers, record 32039434. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32039434

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Structural insights into the promutagenic bypass of the major cisplatin-induced DNA lesion.
PubMed
Journal
Biochem J
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.05
iCite
Revised in PubMed
2020-10-21
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ouzon-Shubeita HHala
2Vilas CKCaroline K
3Lee SSeongmin

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
CisplatinMajor topic
DNA DamageMajor topic
DNA-Directed DNA PolymeraseMajor topic
MutagenesisMajor topic
Crystallography, X-Ray
Humans
Protein Structure, Secondary

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
F31 CA243349NCI NIH HHSUnited StatesF31CA243349PubMed and NIHNIH RePORTER
R01 ES026676NIEHS NIH HHSUnited StatesR01ES026676PubMed and NIHNIH RePORTER

Download CSV of grants

References54

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110357787DNA polymerase beta expression differences in selected human tumors and cell lines.Carcinogenesis1999https://conductscience.org/library/papers/10357787PubMed
222315190Stereospecific formation of a ternary complex of (S)-α,β-fluoromethylene-dATP with DNA pol β.Chembiochem2012https://conductscience.org/library/papers/22315190PubMed
38663082In vitro bypass replication of the cisplatin-d(GpG) lesion by calf thymus DNA polymerase beta and human immunodeficiency virus type I reverse transcriptase is highly mutagenic.J Biol Chem1996https://conductscience.org/library/papers/8663082PubMed
430208165DNA repair pathways and cisplatin resistance: an intimate relationship.Clinics (Sao Paulo)2018https://conductscience.org/library/papers/30208165PubMed
510336894Overexpression of DNA polymerase beta: a genomic instability enhancer process.FASEB J1999https://conductscience.org/library/papers/10336894PubMed
611593426Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents.Oncogene2001https://conductscience.org/library/papers/11593426PubMed
722529383Structural basis of human DNA polymerase η-mediated chemoresistance to cisplatin.Proc Natl Acad Sci U S A2012https://conductscience.org/library/papers/22529383PubMed
830817143Mutagenic Replication of the Major Oxidative Adenine Lesion 7,8-Dihydro-8-oxoadenine by Human DNA Polymerases.J Am Chem Soc2019https://conductscience.org/library/papers/30817143PubMed
910973926Nucleotide excision repair DNA synthesis by excess DNA polymerase beta: a potential source of genetic instability in cancer cells.FASEB J2000https://conductscience.org/library/papers/10973926PubMed
1011827474Involvement of DNA polymerase beta in DNA replication and mutagenic consequences.J Mol Biol2002https://conductscience.org/library/papers/11827474PubMed
1127161042A comprehensive survey of the mutagenic impact of common cancer cytotoxics.Genome Biol2016https://conductscience.org/library/papers/27161042PubMed
1217625587The resurgence of platinum-based cancer chemotherapy.Nat Rev Cancer2007https://conductscience.org/library/papers/17625587PubMed
1310769112Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta.Biochemistry2000https://conductscience.org/library/papers/10769112PubMed
1422659329Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.Pharmacol Rev2012https://conductscience.org/library/papers/22659329PubMed
1525030888C. elegans whole-genome sequencing reveals mutational signatures related to carcinogens and DNA repair deficiency.Genome Res2014https://conductscience.org/library/papers/25030888PubMed
1622178760Binary complex crystal structure of DNA polymerase β reveals multiple conformations of the templating 8-oxoguanine lesion.Proc Natl Acad Sci U S A2012https://conductscience.org/library/papers/22178760PubMed
1721068378Error-prone translesion synthesis mediates acquired chemoresistance.Proc Natl Acad Sci U S A2010https://conductscience.org/library/papers/21068378PubMed
182803953Cisplatin/carboplatin cross-resistance in ovarian cancer.Br J Cancer1989https://conductscience.org/library/papers/2803953PubMed
1912388548A role for DNA polymerase beta in mutagenic UV lesion bypass.J Biol Chem2002https://conductscience.org/library/papers/12388548PubMed
2029232469Acquired chemotherapy resistance in ovarian cancer.Ann Oncol2017https://conductscience.org/library/papers/29232469PubMed

See all 54 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
40142039Structural Insights into the Nonmutagenicity of 2-Haloacetophenone.Molecules2025https://conductscience.org/library/papers/40142039PubMed
35603167Functionalized Lineage Tracing Can Enable the Development of Homogenization-Based Therapeutic Strategies in Cancer.Front Immunol2022https://conductscience.org/library/papers/35603167PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
F102159PubTator's text mininghttps://conductscience.org/library/genes/2159NCBI Gene
LYZ4069PubTator's text mininghttps://conductscience.org/library/genes/4069NCBI Gene
NEB4703PubTator's text mininghttps://conductscience.org/library/genes/4703NCBI Gene
POLB5423PubTator's text mininghttps://conductscience.org/library/genes/5423NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32039434

GET https://conductscience.org/api/papers/v1/32039434/references?page=2